Resmed Q1 FY2027 Earnings Preview: AI, GLP-1s, and Market Dominance

SAN DIEGO, CA – October 01, 2026 – The intersection of medical hardware and digital health is undergoing a seismic shift, and few companies sit closer to the epicenter than Resmed (NYSE: RMD, ASX: RMD). Today, the San Diego-based medical technology giant announced it will release its financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, following the close of the New York Stock Exchange.

The upcoming earnings report arrives at a critical juncture for the sleep apnea and respiratory care industry. Resmed’s leadership will host an exclusive webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Notably, the company has completely transitioned away from traditional dial-in phone lines for live access; the event will be accessible strictly via its investor relations webcast, though a phone replay will be available through November 12.

As market observers and institutional investors mark their calendars, the underlying narrative for Resmed extends far beyond quarterly revenue beats. The company is actively navigating a complex matrix of macroeconomic headwinds, shifting pharmaceutical landscapes, and a massive internal pivot toward artificial intelligence and software-as-a-service (SaaS) ecosystems.

The Financial Landscape and Wall Street Consensus

Heading into the October 29 report, Wall Street consensus anticipates Q1 FY2027 revenue to land at approximately $1.391 billion, with earnings per share (EPS) estimates hovering between $2.58 and $2.68. These figures represent a crucial benchmark for a company striving to maintain the robust momentum it demonstrated at the close of fiscal 2026.

In its Q4 FY2026 report, Resmed delivered an EPS of $2.95, beating consensus estimates of $2.89, while matching revenue expectations at $1.46 billion—an 8.6% year-over-year increase. However, the first quarter of 2027 will not be without its friction points. Investors will be acutely focused on how the company is managing the fallout from the Astral field safety action, which management previously indicated would create a $75 million revenue headwind for FY2027. With a $42 million provision already taken in Q4 2026 and no new Astral sales planned for the current fiscal year, the core continuous positive airway pressure (CPAP) and software segments will need to carry the weight of growth.

Despite these isolated headwinds, Resmed’s capital allocation strategy projects profound confidence. The company recently authorized a massive $1.5 billion stock buyback program for FY2027—including a $450 million accelerated repurchase tied to its MatrixCare divestiture—and hiked its dividend by 10% to $0.66 per share. Analysts will be listening closely during the webcast for updates on the deployment timeline of these repurchases, which provide a strong floor for the stock price amid broader market volatility.

Capitalizing on Competitor Missteps

A significant driver of Resmed’s recent market dominance has been its ability to capitalize on the prolonged struggles of its primary rival, Philips Respironics. Following a devastating June 2021 recall of millions of CPAP and BiPAP devices due to sound abatement foam degradation, Philips has essentially been sidelined in the U.S. market. The resulting regulatory fallout and a stringent consent decree have led to a multi-year exit for Philips, fundamentally altering the competitive duopoly that once defined the sleep apnea hardware market.

Resmed has stepped into this vacuum with remarkable agility. By leveraging superior supply chain flexibility during a period of global logistical strain, the company successfully captured the lion's share of the abandoned market. The upcoming earnings call will provide critical insight into whether Resmed is merely holding onto this newly acquired market share or if it is actively expanding its footprint among durable medical equipment (DME) providers who have permanently shifted their loyalties.

Navigating the GLP-1 Disruption

Perhaps the most hotly debated topic surrounding Resmed—and the broader sleep apnea market—is the meteoric rise of GLP-1 receptor agonists like Ozempic and Wegovy. Because obesity is a primary risk factor for Obstructive Sleep Apnea (OSA), the widespread adoption of these highly effective weight-loss medications initially sparked fears of a shrinking total addressable market for CPAP devices.

However, the reality emerging from clinical studies and physician surveys is far more nuanced. While significant weight loss can undoubtedly alleviate OSA symptoms in some patients, OSA is a complex physiological condition with multiple anatomical and genetic risk factors beyond body mass index. Furthermore, industry analysts suggest that the GLP-1 boom is inadvertently acting as a catalyst for the sleep apnea diagnostic funnel. As patients engage more deeply with their primary care physicians regarding weight management and metabolic health, they are increasingly being screened for comorbidities like sleep apnea.

Resmed’s management has historically maintained a watchful but optimistic stance on this dynamic, emphasizing that increased health awareness drives early diagnosis. During the Q1 webcast, investors will demand updated data on patient flow and diagnostic rates to confirm whether the GLP-1 phenomenon is a headwind or a paradoxical tailwind for device adoption.

Beyond the Mask: A Digital Ecosystem

The most transformative element of Resmed’s long-term strategy—and the central focus of Amanda Clark’s analysis in this column—is the company’s aggressive evolution from a hardware-centric manufacturer into a connected digital health powerhouse. Resmed is no longer just selling masks and motors; it is selling adherence, data, and predictive analytics.

Today, Resmed boasts a staggering network of over 24.5 million cloud-connected medical devices globally. This infrastructure forms the backbone of a highly lucrative SaaS and remote patient monitoring ecosystem. The company’s digital health technologies transmit real-time therapy data to cloud platforms, allowing healthcare providers to monitor patients remotely, adjust treatments dynamically, and significantly reduce the cost of out-of-hospital care.

A prime example of this digital pivot is the December 2025 FDA clearance of "Smart Comfort," an AI-enabled digital medical device that utilizes real-world sleep data and machine learning to recommend personalized comfort settings for OSA patients. By reducing the early friction often associated with CPAP therapy, Smart Comfort directly targets therapy abandonment rates.

Coupled with the myAir consumer app—which now features Apple and Android smartwatch integration alongside a Generative AI-enabled sleep health assistant—Resmed is empowering patients to take ownership of their therapy. The results are tangible: patients using the myAir ecosystem demonstrate an 87% therapy compliance rate, a metric that drives recurring revenue for replacement masks and accessories.

As Resmed prepares to unveil its Q1 FY2027 performance, the numbers on the balance sheet will only tell half the story. The true measure of the company's success will be found in its ability to leverage its massive, AI-driven data ecosystem to insulate itself from pharmaceutical disruptions and solidify its position as the undisputed leader in connected respiratory care.